The role of Rezūm ™ team ablation of the prostate in the treatment of patients with acute urinary retention secondary to benign prostatic hyperplasia. A single center, single surgeon case series and literature review

References

• Dawson C, Whitfield H. ABC of urology. Urological emergencies in general practice. BMJ. 1996;312(7034):838–840.
   PubMed Web of Science ®Google Scholar
• Verhamme KMC, Dieleman JP, van Wijk MAM, et al. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol. 2005;47(4):494–498.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. Rev Urol. 2001;3(4):187–192.
   PubMedGoogle Scholar
• Bardoli AD, Taylor WSJ, Mahmalji W. Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature. Aging Male. 2017;20(3):192–197.
   PubMed Web of Science ®Google Scholar
• Singam P, Hong GE, Ho C, et al. Nocturia in patients with benign prostatic hyperplasia: evaluating the significance of ageing, co-morbid illnesses, lifestyle and medical therapy in treatment outcome in real life practice. Aging Male. 2015;18(2):112–117.
   PubMed Web of Science ®Google Scholar
• Calogero AE, Burgio G, Condorelli RA, et al. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2019;22(1):12–19.
   PubMed Web of Science ®Google Scholar
• Logie J, Clifford GM, Farmer RDT. Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int. 2005;95(4):557–562.
   PubMed Web of Science ®Google Scholar
• Verhamme KMC, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the triumph project. Eur Urol. 2002;42(4):323–328.
   PubMed Web of Science ®Google Scholar
• Kirby RS, Kirby M, Fitzpatrick JM. Benign prostatic hyperplasia: counting the cost of its management. BJU Int. 2010;105(7):901–902.
   PubMed Web of Science ®Google Scholar
• Thomas K, Oades G, Taylor-Hay C, et al. Acute urinary retention: what is the impact on patients' quality of life? BJU Int. 2005;95(1):72–76.
   PubMed Web of Science ®Google Scholar
• Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009;12(1):29–34.
   PubMed Web of Science ®Google Scholar
• Yassin A, Saad F, Hoesl CE, et al. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia. 2006;38(1):1–12.
   PubMed Web of Science ®Google Scholar
• Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19(3):175–181.
   PubMed Web of Science ®Google Scholar
• Mishriki SF, Grimsley SJS, Nabi G, et al. Improved quality of life and enhanced satisfaction after TURP: prospective 12-year follow-up study. Urology. 2008;72(2):322–326.
   PubMed Web of Science ®Google Scholar
• Foster HE, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol. 2018;200(3):612–619.
   PubMed Web of Science ®Google Scholar
• British Association of Urological Surgeons (BAUS). Transurethral Prostatectomy (TURP) for benign disease [Internet]; 2017. Available from: https://www.baus.org.uk/_userfiles/pages/files/Patients/Leaflets/TURP%20for%20benign.pdf.
   Google Scholar
• Rassweiler J, Teber D, Kuntz R, et al. Complications of Transurethral Resection of the Prostate (TURP)—incidence, management, and prevention. Eur Urol. 2006;50(5):969–980.
   PubMed Web of Science ®Google Scholar
• Kirollos MM. Length of postoperative hospital stay after transurethral resection of the prostate. Ann R Coll Surg Engl. 1997;79:284–288.
   PubMed Web of Science ®Google Scholar
• Gravas S, Bach T, Bachmann A. EAU Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) [Internet]; 2020. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-Management-of-non-neurogenic-male-LUTS-2016.pdf.
   Google Scholar
• Sarma D, Singh Y, Baruah SJ, et al. Thulium laser vaporization versus vapoenucleation (without morcellation) technique for BPH: do we have a winner? JELEU. 2019;2(1):e24–e36.
   Google Scholar
• Vazirian-Zadeh M, Anderson J, Gill R, et al. Thulium Laser Enucleation of the Prostate (ThuLEP) as a technique for treatment of BPH: evaluation of a six-year experience at a single institution. JELEU. 2018;1(2):e10–e14.
   Google Scholar
• Montorsi F, Naspro R, Salonia A, et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2004;172(5):1926–1929.
   PubMed Web of Science ®Google Scholar
• Cornu J-N, Ahyai S, Bachmann A, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67(6):1066–1096.
   PubMed Web of Science ®Google Scholar
• Hoey M. Water vapor for tissue ablation. NxThera Inc; 2009.
   Google Scholar
• Green Z, Westwood J, Somani BK. What's new in Rezum: a transurethral water vapour therapy for BPH. Curr Urol Rep. 2019;20(7):39.
   PubMed Web of Science ®Google Scholar
• Westwood J, Geraghty R, Jones P, et al. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol. 2018;10(11):327–333.
   PubMed Web of Science ®Google Scholar
• Dhliwayo B, Mukhtar S. Novel surgical treatments for benign prostatic hyperplasia. JELEU. 2019;2(1):e17–e23.
   Google Scholar
• Elterman D. New less invasive management of BPH. Toronto, Ontario, Canada; 2020 [cited 2020 Oct 24]. Available from: https://content.tts.org/content/videos/cua/MH2020/Dean_Elterman.pdf.
   Google Scholar
• Magistro G, Chapple CR, Elhilali M, et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol. 2017;72(6):986–997.
   PubMed Web of Science ®Google Scholar
• Dixon C, Cedano ER, Pacik D, et al. Efficacy and safety of Rezūm system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2015;86(5):1042–1047.
   PubMed Web of Science ®Google Scholar
• Dixon C, Cedano ER, Mynderse L, et al. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm® system: evaluation of acute ablative capabilities in the human prostate. RRU. 2015;7:13–18.
   Google Scholar
• Burr JM, Hay DJ, Ludgate S, et al. Hot and cold technologies for tissue ablation in urology. BJU Int. 2006;98(6):1149–1153.
   PubMed Web of Science ®Google Scholar
• McNeal JE. The zonal anatomy of the prostate. Prostate. 1981;2(1):35–49.
   PubMed Web of Science ®Google Scholar
• Dixon C, Cedano ER, Pacik D, et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016;8:207–216.
   PubMed Web of Science ®Google Scholar
• Mynderse LA, Hanson D, Robb RA, et al. Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. 2015;86(1):122–127.
   PubMed Web of Science ®Google Scholar
• McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology. 2019;126:171–179.
   PubMed Web of Science ®Google Scholar
• McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529–1538.
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2018;111:1–9.
   PubMed Web of Science ®Google Scholar
• Gupta N, Rogers T, Holland B, et al. Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol. 2018;200(2):405–413.
   PubMed Web of Science ®Google Scholar
• McVary KT, Rogers T, Mahon J, et al. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J Sex Med. 2018;15(12):1728–1738.
   PubMed Web of Science ®Google Scholar